These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12018459)

  • 21. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
    Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
    Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.
    Cho MW; Kim YB; Lee MK; Gupta KC; Ross W; Plishka R; Buckler-White A; Igarashi T; Theodore T; Byrum R; Kemp C; Montefiori DC; Martin MA
    J Virol; 2001 Mar; 75(5):2224-34. PubMed ID: 11160726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.
    Center RJ; Wheatley AK; Campbell SM; Gaeguta AJ; Peut V; Alcantara S; Siebentritt C; Kent SJ; Purcell DF
    Vaccine; 2009 Nov; 27(47):6605-12. PubMed ID: 19712773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.
    Chakrabarti BK; Ling X; Yang ZY; Montefiori DC; Panet A; Kong WP; Welcher B; Louder MK; Mascola JR; Nabel GJ
    Vaccine; 2005 May; 23(26):3434-45. PubMed ID: 15837367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
    Georgiev IS; Doria-Rose NA; Zhou T; Kwon YD; Staupe RP; Moquin S; Chuang GY; Louder MK; Schmidt SD; Altae-Tran HR; Bailer RT; McKee K; Nason M; O'Dell S; Ofek G; Pancera M; Srivatsan S; Shapiro L; Connors M; Migueles SA; Morris L; Nishimura Y; Martin MA; Mascola JR; Kwong PD
    Science; 2013 May; 340(6133):751-6. PubMed ID: 23661761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: significant for vaccine development?
    van Gils MJ; Schuitemaker H
    Curr HIV Res; 2010 Dec; 8(8):579-86. PubMed ID: 21054254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
    Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
    J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
    Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
    J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.
    Lian Y; Srivastava I; Gómez-Román VR; Zur Megede J; Sun Y; Kan E; Hilt S; Engelbrecht S; Himathongkham S; Luciw PA; Otten G; Ulmer JB; Donnelly JJ; Rabussay D; Montefiori D; van Rensburg EJ; Barnett SW
    J Virol; 2005 Nov; 79(21):13338-49. PubMed ID: 16227256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges for structure-based HIV vaccine design.
    Schief WR; Ban YE; Stamatatos L
    Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
    Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K
    Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
    Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
    J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody polyspecificity and neutralization of HIV-1: a hypothesis.
    Haynes BF; Moody MA; Verkoczy L; Kelsoe G; Alam SM
    Hum Antibodies; 2005; 14(3-4):59-67. PubMed ID: 16720975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.
    Astronomo RD; Santra S; Ballweber-Fleming L; Westerberg KG; Mach L; Hensley-McBain T; Sutherland L; Mildenberg B; Morton G; Yates NL; Mize GJ; Pollara J; Hladik F; Ochsenbauer C; Denny TN; Warrier R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Ferrari G; Shaw GM; Xia SM; Liao HX; Montefiori DC; Tomaras GD; Haynes BF; McElrath JM
    EBioMedicine; 2016 Dec; 14():97-111. PubMed ID: 27919754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
    Geiß Y; Dietrich U
    AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.